Anti-carcinogenic activity of Taraxacum plant. II

Biological and Pharmaceutical Bulletin

Volumn 22, Issue 6, 1999, Pages 606-610

  Takasaki, Midori ^a   Konoshima, Takao ^a   Tokuda, Harukuni ^b   Masuda, Kazuo ^c   Arai, Yoko ^c   Shiojima, Kenji ^c   Ageta, Hiroyuki ^c  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Anti carcinogenic activity; Mouse mammary tumor; Mouse skin tumor; Taraxacum japonicum; Taraxasterol; Taraxerol

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; PHORBOL 13 ACETATE 12 MYRISTATE; TARAXASTEROL; TARAXEROL; TRITERPENOID; TUMOR PROMOTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG ISOLATION; DRUG STRUCTURE; FEMALE; MOUSE; NONHUMAN; PLANT ROOT; RAJI CELL; TRADITIONAL MEDICINE;

EID: 0033008655     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.22.606     Document Type: Article

References (22)

1. Takasaki M., Konoshima T., Tokuda H., Masuda K., Arai Y., Shiojima K., Ageta H., Biol. Pharm. Bull., 22, 602-605 (1999).
2. Jiangsu New Medical College (ed.), "Chinese Materia Medica," Shanghai People's Pub. House, Shanghai, 1986, p. 2418; Konoshima M., Shibata S., Shimomura T., Higashi J., (eds.), "Yakuyo Shokubutu Daijiten," Hirokawa Publishing, Tokyo, 1963, p. 213.
3. Jiangsu New Medical College (ed.), "Chinese Materia Medica," Shanghai People's Pub. House, Shanghai, 1986, p. 2418; Konoshima M., Shibata S., Shimomura T., Higashi J., (eds.), "Yakuyo Shokubutu Daijiten," Hirokawa Publishing, Tokyo, 1963, p. 213.
4. Konoshima T., Takasaki M., Tokuda H., Morimoto S., Tanaka H., Kawata E., Xuan L. J., Saito H., Sugiura M., Molnar J., Shoyama Y., Phytother. Res., 12, 400-404 (1998); Konishi T., Takasaki M., Tokuda H., Kiyosawa S., Konoshima T., Biol. Pharm. Bull., 21, 993-996 (1998); Takasaki M., Konoshima T., Yasuda Y., Hamano T. Tokuda H., ibid., 20, 776-780 (1997), and references cited therein.
5. Konoshima T., Takasaki M., Tokuda H., Morimoto S., Tanaka H., Kawata E., Xuan L. J., Saito H., Sugiura M., Molnar J., Shoyama Y., Phytother. Res., 12, 400-404 (1998); Konishi T., Takasaki M., Tokuda H., Kiyosawa S., Konoshima T., Biol. Pharm. Bull., 21, 993-996 (1998); Takasaki M., Konoshima T., Yasuda Y., Hamano T. Tokuda H., ibid., 20, 776-780 (1997), and references cited therein.
6. Konoshima T., Takasaki M., Tokuda H., Morimoto S., Tanaka H., Kawata E., Xuan L. J., Saito H., Sugiura M., Molnar J., Shoyama Y., Phytother. Res., 12, 400-404 (1998); Konishi T., Takasaki M., Tokuda H., Kiyosawa S., Konoshima T., Biol. Pharm. Bull., 21, 993-996 (1998); Takasaki M., Konoshima T., Yasuda Y., Hamano T. Tokuda H., ibid., 20, 776-780 (1997), and references cited therein.
7. Ageta H., Shiojima K., Masuda K., Lin T., Tetrahedron Lett., 22, 2289-2290 (1981).
8. Shiojima K., Masuda K., Suzuki H., Lin T., Ooishi Y., Ageta H., Chem. Pharm. Bull., 43, 1634-1639 (1995).
9. Shiojima K., Suzuki H., Takano A., Kurihara M., Kodera N., Hirano, A., Ageta H., Nat. Med., 51, 125-130 (1997).
10. Shiojima K., Suzuki H., Kodera N., Ageta H., Chem. Pharm. Bull., 44, 509-514 (1996).
11. Jordan V. C., Lababidi M. K., Langan F. S., J. Natl. Cancer Inst., 83, 492-496 (1991); Bradlow H. L., Michnovicz J., Telang N. T, Osborne M. P., Carcinogenesis, 12, 1571-1574 (1991); Jordan V. C., Lababidi M.K., Mirecki D. M., Eur. J. Cancer, 26, 718-721 (1990); Ames I. H., Garcia A. M., John P. A., Litty C. A., Farrell M. A., Tomar R. H., Clin. Immunol. Immunopathol., 38, 265-273 (1986); Silverman J., Powers J., Stromberg P., Pultz J. A., Kent S., Cancer Research, 49, 3857-3860 (1989).
12. Jordan V. C., Lababidi M. K., Langan F. S., J. Natl. Cancer Inst., 83, 492-496 (1991); Bradlow H. L., Michnovicz J., Telang N. T, Osborne M. P., Carcinogenesis, 12, 1571-1574 (1991); Jordan V. C., Lababidi M.K., Mirecki D. M., Eur. J. Cancer, 26, 718-721 (1990); Ames I. H., Garcia A. M., John P. A., Litty C. A., Farrell M. A., Tomar R. H., Clin. Immunol. Immunopathol., 38, 265-273 (1986); Silverman J., Powers J., Stromberg P., Pultz J. A., Kent S., Cancer Research, 49, 3857-3860 (1989).
13. Jordan V. C., Lababidi M. K., Langan F. S., J. Natl. Cancer Inst., 83, 492-496 (1991); Bradlow H. L., Michnovicz J., Telang N. T, Osborne M. P., Carcinogenesis, 12, 1571-1574 (1991); Jordan V. C., Lababidi M.K., Mirecki D. M., Eur. J. Cancer, 26, 718-721 (1990); Ames I. H., Garcia A. M., John P. A., Litty C. A., Farrell M. A., Tomar R. H., Clin. Immunol. Immunopathol., 38, 265-273 (1986); Silverman J., Powers J., Stromberg P., Pultz J. A., Kent S., Cancer Research, 49, 3857-3860 (1989).
14. Jordan V. C., Lababidi M. K., Langan F. S., J. Natl. Cancer Inst., 83, 492-496 (1991); Bradlow H. L., Michnovicz J., Telang N. T, Osborne M. P., Carcinogenesis, 12, 1571-1574 (1991); Jordan V. C., Lababidi M.K., Mirecki D. M., Eur. J. Cancer, 26, 718-721 (1990); Ames I. H., Garcia A. M., John P. A., Litty C. A., Farrell M. A., Tomar R. H., Clin. Immunol. Immunopathol., 38, 265-273 (1986); Silverman J., Powers J., Stromberg P., Pultz J. A., Kent S., Cancer Research, 49, 3857-3860 (1989).
15. Jordan V. C., Lababidi M. K., Langan F. S., J. Natl. Cancer Inst., 83, 492-496 (1991); Bradlow H. L., Michnovicz J., Telang N. T, Osborne M. P., Carcinogenesis, 12, 1571-1574 (1991); Jordan V. C., Lababidi M.K., Mirecki D. M., Eur. J. Cancer, 26, 718-721 (1990); Ames I. H., Garcia A. M., John P. A., Litty C. A., Farrell M. A., Tomar R. H., Clin. Immunol. Immunopathol., 38, 265-273 (1986); Silverman J., Powers J., Stromberg P., Pultz J. A., Kent S., Cancer Research, 49, 3857-3860 (1989).
16. Squartini F., Bolis G. B., Rossi G. R., J. Natl. Cancer Inst., 52, 1635-1641 (1974); Richardson F. L., Hummel K. D., ibid., 23, 91-100 (1959); Squartini F., Rossi G. R., Paoletti I., Nature (London), 197, 505-506 (1963).
17. Squartini F., Bolis G. B., Rossi G. R., J. Natl. Cancer Inst., 52, 1635-1641 (1974); Richardson F. L., Hummel K. D., ibid., 23, 91-100 (1959); Squartini F., Rossi G. R., Paoletti I., Nature (London), 197, 505-506 (1963).
18. Squartini F., Bolis G. B., Rossi G. R., J. Natl. Cancer Inst., 52, 1635-1641 (1974); Richardson F. L., Hummel K. D., ibid., 23, 91-100 (1959); Squartini F., Rossi G. R., Paoletti I., Nature (London), 197, 505-506 (1963).
19. A high viability of Raji cells is necessary for an in vitro assay using an indirect immunofluorescence technique by antigen-antibody reaction and is beneficial for the following in vivo assay.
20. 2 and 1 × 10 mol ratio/TPA, respectively, and the viability percentage of Raji cells was more than 80% at each concentration. Konoshima T., Takasaki M., Tokuda H., Nishino H., Due N.M., Kasai R., Yamasaki K., Biol. Pharm. Bull., 21, 834-838 (1998).
21. 2 and 1 × 10 mol ratio/TPA, respectively, and the viability percentage of Raji cells was more than 80% at each concentration. Tokuda H., Ohigashi H., Koshimizu K., Ito Y, Cancer Lett., 33, 279-282 (1986); Mizutani K., "Food Phytochemicals for Cancer Chemoprevention II., Teas, Spices and Herbs," ed. by Ho C.-T., Osawa T., Huang M.-T., Rosen R. T., American Chemical Society, Washington, D.C., 1994, pp. 322-328.
22. 2 and 1 × 10 mol ratio/TPA, respectively, and the viability percentage of Raji cells was more than 80% at each concentration. Tokuda H., Ohigashi H., Koshimizu K., Ito Y, Cancer Lett., 33, 279-282 (1986); Mizutani K., "Food Phytochemicals for Cancer Chemoprevention II., Teas, Spices and Herbs," ed. by Ho C.-T., Osawa T., Huang M.-T., Rosen R. T., American Chemical Society, Washington, D.C., 1994, pp. 322-328.